Compass Therapeutics (CMPX) Gains from Sales and Divestitures (2020 - 2026)

Compass Therapeutics has disclosed Gains from Sales and Divestitures across 7 years of filings, most recently posting $284000.0 for Q1 2026.

• Gains from Sales and Divestitures for Q1 2026 came in at $284000.0, down 65.49% year-over-year; the trailing twelve-month figure through Mar 2026 was $284000.0 (down 65.49% YoY), and the FY2025 annual result was $1.1 million, up 104.38% from the prior year.
• Gains from Sales and Divestitures came in at $284000.0 for Q1 2026 at Compass Therapeutics, down from $1.1 million in the prior quarter.
• In the past five years, Gains from Sales and Divestitures ranged from a high of $1.1 million in Q4 2025 to a low of $73000.0 in Q1 2022.
• The 5-year median for Gains from Sales and Divestitures is $300000.0 (2022), against an average of $474916.7.
• Across the five-year window, Gains from Sales and Divestitures jumped 265.78% in 2025 and plunged 65.49% in 2026, its largest moves.
• Compass Therapeutics' Gains from Sales and Divestitures stood at $300000.0 in 2022, then changed by 0.0% to $300000.0 in 2023, then surged by 75.0% to $525000.0 in 2024, then soared by 104.38% to $1.1 million in 2025, then slumped by 73.53% to $284000.0 in 2026.
• The last three Gains from Sales and Divestitures figures came in at $284000.0 (Q1 2026), $1.1 million (Q4 2025), and $823000.0 (Q3 2025), per Business Quant data.